Kazia Announces Positive Final Data From Phase II Clinical Study Of Paxalisib In Newly Diagnosed Glioblastoma
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce positive final data from a phase II clinical study of paxalisib as first line therapy...
December 6, 2021
by prnasia
UK trial to assess Sativex for the treatment of ‘aggressive’ brain tumours
A new UK-based trial is set to assess the efficacy of GW Pharma’s cannabis-based drug Sativex as a potential treatment for patients with a recurrent glioblastoma – the most aggressive form of brain tumours.
August 6, 2021
by pharmatimes
Kazia Enters Clinical Collaboration With Cornell University for Phase II Clinical Study Using Paxalisib in Combination With Ketogenic Diet for Glioblastoma
Kazia Therapeutics Limited, an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with the Joan & Sanford I Weill Medical College of Cornell University in the United States, to launch a phase II ...
June 16, 2021
by prnasia
OncoSynergy Announces First Patient Treated in OS2966 Trial of Recurrent Glioblastoma
OncoSynergy announced the first patient was treated in the Company's First-in-Human Phase 1 clinical trial evaluating OS2966 for the treatment of recurrent glioblastoma at Moffitt Cancer Center in Tampa, Florida.
March 10, 2021
by americanpharmaceuticalreview
IGV-001 demonstrates success against glioblastoma in Phase Ib trial
Imvax’s Phase Ib clinical trial of IGV-001 for patients with newly diagnosed glioblastoma has shown positive results.
January 28, 2021
by europeanpharmaceuticalreview
First Patient Dosed in Biomarker-Guided Study of DB102 for Newly-Diagnosed Glioblastoma
Denovo Biopharma announced dosing of the first patient in its biomarker guided Phase 3 clinical study evaluating the DB102 (enzastaurin) in combination with temozolomide and radiation as first line therapy to treat newly-diagnosed glioblastoma ...
January 15, 2021
by americanpharmaceuticalreview
Innovent Announces NMPA Approves BYVASDA for Adult Recurrent Glioblastoma
Innovent Biologics has announced BYVASDA® (bevacizumab biosimilar), a recombinant humanized anti-VEGF monoclonal antibody drug independently developed by Innovent, has been officially approved by the National Medical Products Administration (NMPA) of ...
January 8, 2021
by americanpharmaceuticalreview
Innovent Announces the NMPA Granted New Indication Approval for BYVASDA® (Bevacizumab Biosimilar) for the Treatment of Adult Recurrent Glioblastoma
Innovent Biologics, Inc., a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announces that BYVASDA® ...
December 28, 2020
by prnasia
AIVITA Biomedical's Glioblastoma Trial Shows Improved Progression Free Survival
AIVITA Biomedical announced data from its multi-center Phase 2 clinical trial of its personalized cancer vaccine, AV-GBM-1, in patients with newly diagnosed glioblastoma (GBM).
December 2, 2020
by americanpharmaceuticalreview
Pelareorep-based combination therapy improves glioblastoma patient survival
In a Phase Ib trial, pelareorep with GM-CSF, chemoradiotherapy and temozolomide increased progression-free survival by an average of eight months.
November 26, 2020
by europeanpharmaceuticalreview
AIVITA Biomedical Completes Treatment of Patients in Glioblastoma Immunotherapy Trial
AIVITA Biomedical announced treatment has been completed for all 57 patients in the Phase 2 clinical trial of AV-GBM-1 in patients with glioblastoma.
November 11, 2020
by americanpharmaceuticalreview
Trodelvy from Immunomedics gets US FDA orphan drug designation for glioblastoma
Trodelvy has shown encouraging activity in an early-stage study in brain cancers, including partial responses in small cohorts of patients with brain metastasis from breast cancer and recurrent glioblastoma, informed the company.
October 14, 2020
by expresspharma